Alteration of gene expression and DNA methylation in drug-resistant gastric cancer

Oncology Reports

Volumn 31, Issue 4, 2014, Pages 1883-1890

  Maeda, Osamu ^a   Ando, Takafumi ^a   Ohmiya, Naoki ^b   Ishiguro, Kazuhiro ^a   Watanabe, Osamu ^a   Miyahara, Ryoji ^a   Hibi, Yoko ^c   Nagai, Taku ^c   Yamada, Kiyofumi ^c   Goto, Hidemi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

5 fluorouracil; Cisplatin; DNA methylation; Drug resistance; Gastric cancer

Indexed keywords

CISPLATIN; FLUOROURACIL; KALLIKREIN 13; NOTCH3 RECEPTOR;

ARTICLE; CANCER CELL; CASE REPORT; CONTROLLED STUDY; CPT1C GENE; DNA METHYLATION; ETV7 GENE; FSCN1 GENE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; KLK13 GENE; MICROARRAY ANALYSIS; NOTCH3 GENE; PRIORITY JOURNAL; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH CANCER;

ANTINEOPLASTIC AGENTS; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; TRANSCRIPTOME;

EID: 84908129534     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3014     Document Type: Article

References (22)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Okines A, Verheij M, Allum W, Cunningham D, Cervantes A; ESMO Guidelines Working Group: Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 (Suppl 5): v50-v54, 2010.
3. Zhang D and Fan D: New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. Future Oncol 6: 527-537, 2010.
4. Taby R and Issa JP: Cancer epigenetics. CA Cancer J Clin 60: 376-392, 2010.
5. Ushijima T: Epigenetic field for cancerization. J Biochem Mol Biol 40: 142-150, 2007.
6. Shen L, Kondo Y, Ahmed S, et al: Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Res 67: 11335-11343, 2007.
7. Yamashita S, Takahashi S, McDonell N, et al: Methylation silencing of transforming growth factor-β receptor type II in rat prostate cancers. Cancer Res 68: 2112-2121, 2008.
8. Koizumi W, Narahara H, Hara T, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9: 215-221, 2008.
9. Bibikova M, Barnes B, Tsan C, et al: High density DNA methylation array with single CpG site resolution. Genomics 98: 288-295, 2011.
10. Colella S, Shen L, Baggerly KA, Issa JP and Krahe R: Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 35: 146-150, 2003.
11. An B, Kondo Y, Okamoto Y, et al: Characteristic methylation profile in CpG island methylator phenotype-negative distal colorectal cancers. Int J Cancer 127: 2095-2105, 2010.
12. Shen L, Guo Y, Chen X, Ahmed S and Issa JP: Optimizing annealing temperature overcomes bias in bisulfite PCR methylation analysis. Biotechniques 42: 48-58, 2007.
13. Chou RH, Lin SC, Wen HC, Wu CW and Chang WS: Epigenetic activation of human kallikrein 13 enhances malignancy of lung adenocarcinoma by promoting N-cadherin expression and laminin degradation. Biochem Biophys Res Commun 409: 442-447, 2011.
14. Florou D, Mavridis K and Scorilas A: The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents. Tumour Biol 33: 2069-2078, 2012.
15. Gu X, Shin BH, Akbarali Y, et al: Tel-2 is a novel transcriptional repressor related to the Ets factor Tel/ETV-6. J Biol Chem 276: 9421-9436, 2001.
16. Hanker LC, Karn T, Holtrich U, et al: Prognostic impact of fascin-1 (FSCN1) in epithelial ovarian cancer. Anticancer Res 33: 371-377, 2013.
17. Tsai WC, Jin JS, Chang WK, et al: Association of cortactin and fascin-1 expression in gastric adenocarcinoma: correlation with clinicopathological parameters. J Histochem Cytochem 55: 955-962, 2007.
18. Reilly PT and Mak TW: Molecular pathways: tumor cells co-opt the brain-specific metabolism gene CPT1C to promote survival. Clin Cancer Res 18: 5850-5855, 2012.
19. Liu J, Fan H, Ma Y, et al: Notch1 is a 5-fluorouracil resistant and poor survival marker in human esophagus squamous cell carcinomas. PLoS One 8: e56141, 2013.
20. Ma XB, Jia XS, Liu YL, et al: Expression and role of Notch signalling in the regeneration of rat tracheal epithelium. Cell Prolif 42: 15-28, 2009.
21. Man CH, Wei-Man Lun S, Wai-Ying Hui J, et al: Inhibition of NOTCH3 signalling significantly enhances sensitivity to cisplatin in EBV-associated nasopharyngeal carcinoma. J Pathol 226: 471-481, 2012.
22. Rahman MT, Nakayama K, Rahman M, et al: Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer. Am J Clin Pathol 138: 535-544, 2012.